Download PDF
TumorDiagnostik & Therapie 2019; 40(08): 513-516
DOI: 10.1055/a-0961-8569
Schwerpunkt Endokrine Tumoren
© Georg Thieme Verlag KG Stuttgart · New York

Leitliniengerechte Therapie des Nebennierenkarzinoms

Reinhard Merz
Further Information

Publication History

Publication Date:
12 September 2019 (online)

Also available at
    Permissions and Reprints

Das Nebennierenkarzinom zählt zu den seltenen Tumorerkrankungen und ist sehr aggressiv. Die 2018 erschienene europäische Leitlinie gibt Hinweise auf ein strukturiertes Vorgehen bei Diagnostik und Therapie.
 

  • Literatur

  • 1 Koschker AC, Fassnacht M, Hahner S. et al. Adrenocortical carcinoma – improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes 2006; 114: 45-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Niederle B, Kaserer K, Kurtaran A. et al. Nebennierentumoren. In: Hiddemann W, Bartram C. (Hrsg) Die Onkologie. Springer-Verlag; 2010
    Google Scholar
  • 3 Fernandez-Real JM, Engel WR, Simo R. et al. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clin Endocrinol 1998; 49: 53-61
    CrossrefPubMedGoogle Scholar
  • 4 Vierhapper H, Heinze G, Gessl A. et al. Adrenocortical tumors: Prevalence of impaired glucose tolerance and of “Paradoxical Rise” of cortisol during an oral glucose tolerance test. Exp Clin Endocrinol Diabetes 2003; 111: 415-420
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Fassnacht M, Libé R, Kroiss M. et al. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011; 7: 323-335
    PubMedGoogle Scholar
  • 6 Fassnacht M, Johanssen S, Quinkler M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115: 243-250
    CrossrefPubMedGoogle Scholar
  • 7 Lughezzani G, Sun M, Perrotte P. et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010; 46: 713-719
    CrossrefPubMedGoogle Scholar
  • 8 Fassnacht M, Dekkers O, Else T. et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018; 179: G1-G46
    CrossrefPubMedGoogle Scholar
  • 9 Kroiss M, Plonne D, Kendl S. et al. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 2016; 174: 343-353
    CrossrefPubMedGoogle Scholar
  • 10 Sbiera S, Leich E, Liebisch G. et al. Mitotane inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 2015; 156: 3895-3908
    CrossrefPubMedGoogle Scholar
  • 11 Fassnacht M, Terzolo M, Allolio B. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197
    CrossrefPubMedGoogle Scholar
  • 12 Terzolo M, Zaggia B, Allasino B. et al. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2014; 21: 159-165
    CrossrefPubMedGoogle Scholar
  • 13 www.epiclin.it/adiuvo . Zugegriffen: 2. August 2019
    PubMed
  • 14 Megerle F, Fassnacht M. Medikamentöse Therapie des Nebennierenkarzinoms. Onkologe 2018; 24: 118-123
    CrossrefPubMedGoogle Scholar